Table 1 Patient characteristics.

N

106

272

117

426

Age

Mean ± SD

53.1 ± 12.0

57.6 ± 13.0

56.7 ± 12.3

56.5 ± 12.5

Body mass index

Median (IQR)

21.6 (19.5–25.0)

21.8 (19.4–23.9)

22.2 (19.3–25.0)

21.8 (19.2–25.3)

Smoking history

Yes N(%)

36 (34.0%)

107 (39.3%)

36 (30.8%)

167 (39.2%)

Alcohol consumption history

Yes N(%)

34 (32.1%)

92 (33.8%)

31 (26.5%)

139 (32.6%)

Use of corticosteroids

Yes N(%)

2 (1.9%)

2 (0.7%)

4 (3.4%)

13 (3.1%)

Use of immunosuppressive agents

Yes N(%)

1 (0.9%)

1 (0.4%)

0 (0.0%)

3 (0.7%)

Prior chemotherapy

Yes N(%)

14 (13.2%)

27 (9.9%)

7 (6.0%)

28 (6.6%)

Opioid use

Yes N(%)

19 (17.9%)

11 (4.0%)

15 (12.8%)

29 (6.8%)

Total radiation dose

Mean ± SD

54.1 ± 29.2

60.1 ± 18.1

44.8 ± 26.4

63.4 ± 17.5

Cancer stage

I N(%)

27 (25.5%)

84 (30.9%)

15 (12.8%)

68 (16.0%)

II N(%)

46 (43.4%)

112 (41.2%)

29 (24.8%)

137 (32.2%)

III N(%)

21 (19.8%)

40 (14.7%)

58 (49.6%)

176 (41.3%)

IV N(%)

12 (11.3%)

36 (13.2%)

15 (12.8%)

44 (10.3%)

Albumin levels (g/dl)

Median (IQR)

4.0 (3.5—4.2)

3.9 (3.5—4.1)

3.9 (3.4—4.2)

3.9 (3.5–4.2)

White blood cell counts

Median (IQR)

5605.0 (4325.0—7377.5)

5800.0 (4400.0—7242.5)

5840.0 (4800.0—7900.0)

6500.0 (4900.0–8497.5)

Neutrophils counts

Median (IQR)

3500.0 (2560.0—5328.0)

3950.0 (2810.0—5137.0)

3710.0 (2950.0—6042.0)

4320.0 (3054.0–6006.0)

Platelet counts

Median (IQR)

28.0 (22.3—33.8)

27.2 (22.4—36.9)

27.3 (22.6—34.9)

28.8 (23.1–36.8)

Total protein

Median (IQR)

6.9 (6.6—7.3)

6.9 (6.4—7.3)

7.0 (6.5—7.4)

7.0 (6.5–7.4)

Olanzapine use

Yes N(%)

4 (3.8%)

20 (7.4%)

14 (12.0%)

48 (11.3%)

NK1 receptor antagonist use

Yes N(%)

39 (36.8%)

199 (73.2%)

48 (41.0%)

338 (79.3%)

5-HT3receptor antagonist use

Granisetron N(%)

56 (52.8%)

47 (17.3%)

54 (46.2%)

60 (14.1%)

Palonosetron N(%)

50 (47.2%)

225 (82.7%)

63 (53.8%)

366 (85.9%)